STING agonist compound 3 is primarily utilized in immunotherapy research, particularly in the development of cancer treatments. It activates the STING (Stimulator of Interferon Genes) pathway, which plays a crucial role in the immune response against tumors. By stimulating this pathway, it enhances the production of type I interferons and other cytokines, promoting anti-tumor immunity. This compound is often studied in preclinical models to evaluate its potential in boosting the efficacy of cancer vaccines and checkpoint inhibitors. Additionally, it is explored for its ability to improve the immune system's recognition and destruction of cancer cells, making it a promising candidate for combination therapies in oncology.